Literature DB >> 22229575

Nitric oxide and L-arginine deficiency in cystic fibrosis.

Hartmut Grasemann1, Felix Ratjen.   

Abstract

The concentrations of nitric oxide are decreased in airways of patients with cystic fibrosis. The reasons for this nitric oxide deficiency are incompletely understood but may include reduced production from nitric oxide synthases due to decreased expression, the enzymes in airway epithelial cells, reduced availability of L-arginine, the substrate for nitric oxide synthases, and the presence of endogenous inhibitors of the enzymes in the airways. As nitric oxide plays a role in a number of important physiological processes in the lung including host defense against pathogens such as Pseudomonas aeruginosa, inflammation and the regulation of vascular and broncho motor tone, the lack of nitric oxide may contribute to lung disease in cystic fibrosis patients. Therapeutic interventions aiming to correct the nitric oxide deficiency in the cystic fibrosis airways are therefore currently being explored as new therapies for these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22229575     DOI: 10.2174/138161212799315911

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  18 in total

1.  Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study.

Authors:  Caroline Deppisch; Gloria Herrmann; Ute Graepler-Mainka; Hubertus Wirtz; Susanne Heyder; Corinna Engel; Matthias Marschal; Christopher C Miller; Joachim Riethmüller
Journal:  Infection       Date:  2016-02-09       Impact factor: 3.553

2.  Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.

Authors:  Sarah A Ingersoll; Julie Laval; Osric A Forrest; Marcela Preininger; Milton R Brown; Dalia Arafat; Greg Gibson; Vin Tangpricha; Rabindra Tirouvanziam
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

Review 3.  New insights into upper airway innate immunity.

Authors:  Benjamin M Hariri; Noam A Cohen
Journal:  Am J Rhinol Allergy       Date:  2016-09       Impact factor: 2.467

4.  CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Orphan Drugs       Date:  2016-09-13       Impact factor: 0.694

5.  Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation.

Authors:  Kate B Twomey; Mark Alston; Shi-Qi An; Oisin J O'Connell; Yvonne McCarthy; David Swarbreck; Melanie Febrer; J Maxwell Dow; Barry J Plant; Robert P Ryan
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

Review 6.  The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections.

Authors:  Daniel J Hassett; Rhett A Kovall; Michael J Schurr; Nalinikanth Kotagiri; Harshita Kumari; Latha Satish
Journal:  Front Microbiol       Date:  2021-06-17       Impact factor: 5.640

7.  L-ornithine derived polyamines in cystic fibrosis airways.

Authors:  Hartmut Grasemann; Darakhshanda Shehnaz; Masahiro Enomoto; Michael Leadley; Jaques Belik; Felix Ratjen
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

8.  Oscillatory shear stress-induced arginase activity may explain reduced exhaled nitric oxide levels after vest chest physiotherapy in cystic fibrosis.

Authors:  Christoph Nowak
Journal:  Pulm Med       Date:  2014-04-03

9.  Effect of arginase inhibition on pulmonary L-arginine metabolism in murine Pseudomonas pneumonia.

Authors:  Anne Mehl; Peyman Ghorbani; David Douda; Hailu Huang; Nades Palaniyar; Felix Ratjen; Hartmut Grasemann
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

10.  Multitracer stable isotope quantification of arginase and nitric oxide synthase activity in a mouse model of pseudomonas lung infection.

Authors:  Hartmut Grasemann; Thomas Jaecklin; Anne Mehl; Hailu Huang; Mahroukh Rafii; Paul Pencharz; Felix Ratjen
Journal:  Mediators Inflamm       Date:  2014-08-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.